Improved genome-editing via oviductal nucleic acid delivery (i-GONAD) is a technique capable of inducing genomic changes in preimplantation embryos (zygotes) present within the oviduct of a pregnant female. i-GONAD involves intraoviductal injection of a solution containing genome-editing components via a glass micropipette under a dissecting microscope, followed by in vivo electroporation using tweezer-type electrodes. i-GONAD does not involve ex vivo handling of embryos (isolation of zygotes, microinjection or electroporation of zygotes, and egg transfer of the treated embryos to the oviducts of a recipient female), which is required for in vitro genome-editing of zygotes. i-GONAD enables the generation of indels, knock-in (KI) of ~ 1 kb sequence of interest, and large deletion at a target locus. i-GONAD is usually performed on Day 0.7 of pregnancy, which corresponds to the late zygote stage. During the initial development of this technique, we performed i-GONAD on Days 1.4-1.5 (corresponding to the 2-cell stage). Theoretically, this means that at least two GONAD steps (on Day 0.7 and Day 1.4-1.5) must be performed. If this is practically demonstrated, it provides additional options for various clustered regularly interspaced palindrome repeats (CRISPR)/Caspase 9 (Cas9)-based genetic manipulations. For example, it is usually difficult to induce two independent indels at the target sites, which are located very close to each other, by simultaneous transfection of two guide RNAs and Cas9 protein. However, the sequential induction of indels at a target site may be possible when repeated i-GONAD is performed on different days. Furthermore, simultaneous introduction of two mutated lox sites (to which Cre recombinase bind) for making a floxed allele is reported to be difficult, as it often causes deletion of a sequence between the two gRNA target sites. However, differential KI of lox sites may be possible when repeated i-GONAD is performed on different days. In this study, we performed proof-of-principle experiments to demonstrate the feasibility of the proposed approach called "sequential i-GONAD (si-GONAD)."
Keywords: Cre/loxP; electroporation; genome-editing; i-GONAD; in vivo gene delivery; indels; knock-in; oviducts.
Conflict of interest statement
The founding sponsors had no role in the design of the study and were not involved in the collection, analysis, or interpretation of data.
i-GONAD: A method for generating genome-edited animals without ex vivo handling of embryos.Dev Growth Differ. 2019 Jun;61(5):306-315. doi: 10.1111/dgd.12620. Epub 2019 Jun 14. Dev Growth Differ. 2019. PMID: 31198998 Review.
Creation of CRISPR-based germline-genome-engineered mice without ex vivo handling of zygotes by i-GONAD.Nat Protoc. 2019 Aug;14(8):2452-2482. doi: 10.1038/s41596-019-0187-x. Epub 2019 Jul 24. Nat Protoc. 2019. PMID: 31341289
i-GONAD (improved genome-editing via oviductal nucleic acids delivery), a convenient in vivo tool to produce genome-edited rats.Sci Rep. 2018 Aug 13;8(1):12059. doi: 10.1038/s41598-018-30137-x. Sci Rep. 2018. PMID: 30104681 Free PMC article.
GONAD: Genome-editing via Oviductal Nucleic Acids Delivery system: a novel microinjection independent genome engineering method in mice.Sci Rep. 2015 Jun 22;5:11406. doi: 10.1038/srep11406. Sci Rep. 2015. PMID: 26096991 Free PMC article.
In vivo genome editing targeted towards the female reproductive system.Arch Pharm Res. 2018 Sep;41(9):898-910. doi: 10.1007/s12272-018-1053-z. Epub 2018 Jul 4. Arch Pharm Res. 2018. PMID: 29974342 Review.